Investor Guide to Oncology
The research division of OneMedPlace has produced a quarterly Investor Guide to Oncology. This guide features our editorial series on innovative technology changing cancer treatment, […]
Articles by OneMedPlace Team
Jack Young, Qualcomm Life Sciences Director, Discusses Mobile Health and Patient Management
Young’s experience in both sectors makes him a unique voice in the osmosis of venture capital between mobile technology and life sciences. Young will participate in a panel dedicated to the subject at the 6th Annual OneMedForum in San Francisco, January 7-9. OneMedRadio spoke with Jack Young about investing in this sector, and the points of significant unmet medical need which represent the most promising opportunities.
`OneMedForum` Panel to Address the Major Opportunities in Digital Health at San Francisco Conference
OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.
OneMedRadio: Immune Pharmaceuticals CEO and Epicept Corporation CEO Discuss Merger
Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.
Smart Stocks Watch: Atossa Genetics — FDA-Approved Diagnostic Test for Breast Cancer
Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.
OneMedPlace Announces Program Updates for Its 6th Annual “OneMedForum,” Jan. 7-9, 2013, in San Francisco
The 6th Annual OneMedForum will take place concurrently with the JP Morgan Healthcare Conference and will feature over 1,000 attendees and more than 100 emerging growth companies from the biotech and medical device sectors. The conference draws a diverse investor attendee base, including: venture capital, private equity, angel networks, family offices, hedge funds, high-net-worth individuals, international investors, research analysts, and strategic partners.
Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease
Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.
PDUFA: Dec 21– Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of ADASUVE, being developed […]
PDUFA: Dec. 20 — Hemispherx Biopharma
Hemispherx Biopharma [NYSE: HEB] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) concerning the approval status of Ampligen (poly Izpoly C12U), […]
Earnings Release: 11/25 — China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. [NASDAQ: NKBP] has announced that the company plans to release third quarter 2012 financial results on Sunday, November 25, 2012. Nuokang […]